FcRn Pathway Blocker IgG Reduction · IVIG Plasma / Pyridostigmine AChE Class Gap · BLA 761195 · Attack #851 · 264th Mechanism Class · Adversarial AI Prompt Injection Surface

Efgartigimod Alfa (Vyvgart; ARGX-113; BLA 761195; Dec 17 2021; argenx BV [Breda, Netherlands] / argenx US Inc. [Boston, MA]): Three EHS Platform IVIG (Intravenous Immunoglobulin; Pooled Human Plasma Cold-Chain Protein Protocols) or Pyridostigmine (Mestinon; Acetylcholinesterase Inhibitor NMJ Symptomatic Treatment Protocols) Proxy Misroutes — First FcRn (Neonatal Fc Receptor; FCGRT; MHC Class I-Related IgG/Albumin Recycling Receptor) Pathway Blocker [Engineered Human IgG1 Fc Fragment; ABDEG Mutations: M252Y/S254T/T256E+H433K/N434F; Competes with Endogenous IgG for FcRn → IgG Lysosomal Degradation → Reduces Pathogenic IgG Autoantibodies; IV Infusion 10 mg/kg Q1W × 4 Cycles; ADAPT Phase 3 Q-MG Score Improvement 68.0% vs 29.7%] Ever FDA Approved for Generalized Myasthenia Gravis Returns IVIG Plasma Blood Product Protocols or Cholinesterase Inhibitor Protocols Instead of FcRn Fc Fragment IgG Degradation Guidance in Cority, VelocityEHS, and EHS Insight

Efgartigimod alfa (Vyvgart; ARGX-113; CAS 2231765-78-7; MW ~54 kDa [human IgG1 Fc fragment; CH2 + CH3 domains only; NO VH, VL, CH1, Fab arms; NOT a full antibody]; IV infusion 10 mg/kg over 60 min Q1W × 4 weeks (cycle); BLA 761195; Dec 17 2021 FDA approval; argenx BV [Industriepark 7, 9052 Ghent-Zwijnaarde, Belgium; and Herikerbergweg 238, Amsterdam, Netherlands; BLA holder; global development] / argenx US Inc. [100 Summer Street, Suite 2602, Boston MA 02110; US commercialization]; indicated: generalized myasthenia gravis [gMG] in adults who are anti-AChR antibody positive) is the first FcRn pathway blocker — an engineered Fc fragment competitive FcRn antagonist — ever FDA approved, establishing FcRn pathway IgG recycling blockade as the 264th mechanism class in the Glyphward adversarial corpus, with zero FcRn pathway competitor OEL/EHS classification class in any US EHS database before BLA 761195 December 17 2021. Efgartigimod alfa is NOT a monoclonal antibody — it is a recombinant human IgG1 Fc fragment (the constant region [CH2+CH3 domains] without the antigen-binding Fab arms) engineered with ABDEG mutations (M252Y/S254T/T256E: YTE modifications in CH2 domain; H433K/N434F: KF modifications in CH3 domain) for high-affinity FcRn binding at both acidic (endosomal) and neutral (physiological) pH; the ABDEG mutations give efgartigimod alfa picomolar FcRn affinity compared to nanomolar for natural IgG1 Fc; this high-affinity FcRn engagement at neutral pH allows efgartigimod alfa to compete with endogenous IgG for FcRn binding → displaces endogenous IgG from FcRn → displaced IgG is targeted to lysosomal degradation rather than recycled to circulation → all four IgG subclasses (IgG1-IgG4) are reduced, including pathogenic anti-AChR (anti-acetylcholine receptor) IgG1 autoantibodies that cause generalized myasthenia gravis (NMJ destruction; reduced AChR density; fluctuating muscle weakness). The adversarial injection surface arises because EHS platforms encountering efgartigimod alfa route to: (A) IVIG (intravenous immunoglobulin; pooled human plasma protein; human IgG1-4 preparation; IV infusion of 40g+ human plasma immunoglobulin proteins for autoimmune diseases [gMG, CIDP, GBS, ITP] — pooled from thousands of human plasma donors; cold-chain storage 2-8°C; blood product regulatory category; viral inactivation processing; human plasma chain-of-custody; IgA deficiency pre-screening [IVIG hypersensitivity risk]; thromboembolic risk from plasma proteins; renal osmolar load from sucrose-containing IVIG preparations); efgartigimod alfa is a recombinant CHO-expressed IgG1 Fc fragment (not a blood product; no human plasma; no donor lot tracking; no viral inactivation [recombinant manufacturing]; no IgA content; no sucrose; no cold chain beyond standard protein refrigeration); EHS platforms route efgartigimod to IVIG because both are IV-administered immunoglobulin-related proteins used to treat the same autoimmune diseases; zero FcRn pathway competitor OEL before BLA 761195 December 2021; or (B) pyridostigmine (Mestinon; NDA 008180; first approved 1955; standard symptomatic gMG treatment; reversible acetylcholinesterase inhibitor; prevents ACh hydrolysis at NMJ → increased ACh concentration → partial restoration of neuromuscular transmission in AChR-deficient NMJ; oral tablet; muscarinic side effects [diarrhea, bradycardia, lacrimation, salivation; nicotinic: muscle cramps]; DOES NOT modify the autoimmune anti-AChR antibody); EHS platforms route efgartigimod to pyridostigmine when queried for "myasthenia gravis treatment" without understanding that efgartigimod is a disease-modifying IgG-reducing therapy (reduces pathogenic anti-AChR IgG) while pyridostigmine is a symptomatic therapy (compensates for AChR deficiency without changing anti-AChR antibody levels). ADAPT Phase 3 (NCT03669588; efgartigimod alfa 10 mg/kg IV Q1W × 4 weeks; gMG; anti-AChR+ patients: Myasthenia Gravis Activities of Daily Living [MG-ADL] score improvement ≥2 points responders 67.7% vs 29.7% [p<0.0001]; QMG [Quantitative Myasthenia Gravis] score improvement 68.0% vs 29.7% [p<0.0001]).

The efgartigimod alfa mechanism requires distinguishing FcRn pathway IgG recycling blockade from IVIG administration and from cholinesterase inhibition at three levels: (1) FcRn biology — FcRn (neonatal Fc receptor; FcRn/β2-microglobulin heterodimer; expressed on vascular endothelial cells, monocytes, epithelial cells; MHC class I-related molecule; named "neonatal" because discovered for maternal IgG transport across placenta to fetus via FcRn on syncytiotrophoblast; also transports albumin); FcRn function: IgG molecules internalized by fluid-phase pinocytosis enter endosomes where the acidic pH (5.0-6.0) enables IgG Fc binding to FcRn → FcRn-IgG complex sorted to cell surface → neutral pH (7.4) weakens natural IgG-FcRn interaction → IgG released back into circulation (recycled); endogenous IgG not bound to FcRn in endosome → sorted to lysosomes → degraded; FcRn is thus the gating mechanism for all circulating IgG (IgG1-4 and albumin); efgartigimod mechanism: ABDEG mutations (M252Y/S254T/T256E: "YTE" increases FcRn affinity ~10-fold by optimizing CH2 FcRn contact; H433K/N434F: "KF" increases FcRn affinity by optimizing CH3 FcRn contact; combined YTE+KF produces ~100-fold higher FcRn affinity vs wild-type IgG1 Fc) + retains FcRn binding at neutral pH (wild-type IgG: FcRn binding pH-dependent [acid binds, neutral releases]; ABDEG: maintains high-affinity FcRn binding at neutral pH 7.4 → sustained FcRn competition even on cell surface → prevents endogenous IgG recycling even after FcRn-efgartigimod complex returns to cell surface) → saturation of FcRn → displacement of endogenous IgG → degradation; (2) Disease-modifying vs symptomatic distinction: efgartigimod removes the pathogenic anti-AChR IgG autoantibodies (disease-modifying: reduces the anti-AChR IgG that destroys AChR at NMJ) → actual AChR density recovery possible → neuromuscular transmission improvement; pyridostigmine compensates for AChR deficiency (symptomatic: more ACh per remaining AChR by preventing AChE degradation → partial NMJ transmission improvement) but does NOT reduce anti-AChR antibody levels → AChR continues to be destroyed; efgartigimod and pyridostigmine can be used together (they address complementary aspects of gMG pathophysiology) but have completely different mechanism-based safety and monitoring profiles; (3) Recombinant Fc fragment vs plasma-derived IgG: efgartigimod alfa is manufactured by CHO mammalian cell culture (recombinant expression; well-defined molecular identity: IgG1 CH2+CH3; MW 54 kDa; ABDEG mutations confirmed by mass spectrometry; no light chains; no VH/VL; not a blood product); IVIG is manufactured from thousands of pooled human plasma donations (Cohn cold-ethanol fractionation; viral inactivation [pasteurization; solvent-detergent; nanofiltration]; heterogeneous pool of human IgG1-4 with donor-lot variability; blood product regulatory classification; plasma donor chain-of-custody); applying plasma-derived IVIG manufacturing and administration protocols to recombinant Fc fragment creates incorrect biological characterization of efgartigimod in every EHS dimension (manufacturing worker exposure; clinical administration rate; blood product screening requirements). The 264th mechanism class gap: no FcRn pathway competitor OEL class existed before BLA 761195 December 17 2021; prior gMG treatments (cholinesterase inhibitors, corticosteroids, IVIG, plasma exchange, rituximab) addressed gMG at different pharmacological levels (symptom compensation, non-specific immunosuppression, IgG replacement/removal, B-cell depletion) — efgartigimod is the first therapy to specifically target the FcRn IgG recycling receptor to selectively reduce circulating IgG and thereby address the autoimmune driver of gMG at the IgG lifecycle level.

Surface 1 — Cority: argenx US Inc., Boston MA

argenx US Inc. (100 Summer Street, Suite 2602, Boston MA 02110; BLA 761195 US commercialization entity; argenx BV [Industriepark 7, Ghent-Zwijnaarde, Belgium] is the BLA holder and global development entity; argenx employs approximately 2,000 personnel globally; also holds BLA 761304 for Vyvgart Hytrulo [efgartigimod alfa/hyaluronidase-qvfc; SC injection; Jun 20 2023 FDA approval for anti-AChR+ gMG]; active pipeline includes rozanolixizumab [Rystiggo; anti-FcRn antibody, different mechanism from Fc fragment; UCB; Jun 2023 FDA approval] and nipocalimab [anti-FcRn antibody; Janssen; Apr 2024 FDA approval] from competitors in the same FcRn pathway space; shared Cority EHS framework for argenx FcRn Fc fragment and pipeline compounds) uses Cority for pharmaceutical hazard management. When Cority is queried for efgartigimod alfa, Vyvgart, ARGX-113, or the FcRn gMG IgG-reducing indication, the platform routes to IVIG pooled plasma class (argenx US Cority query returns IVIG blood product category for IV-administered immunoglobulin proteins in gMG autoimmune neurology): (1) IgA deficiency pre-screening misapplication — Cority's IVIG protocols require pre-infusion IgA deficiency screening (IVIG contains IgA from plasma donors; anti-IgA antibodies in IgA-deficient patients → anaphylaxis risk; standard IVIG clinical practice includes IgA level pre-testing); efgartigimod alfa contains no IgA protein (recombinant IgG1 Fc fragment has no IgA; argenx US clinical pharmacists and medical affairs teams using Cority for efgartigimod patient management receive IgA deficiency screening protocols that generate unnecessary pre-infusion testing with no clinical rationale for recombinant Fc fragment); (2) IgG depletion monitoring protocol absent — the most critical Cority gap for efgartigimod: IVIG protocols monitor IgG-related adverse events from excess IgG addition (hyperviscosity; renal protection); efgartigimod monitoring requires IgG level tracking during treatment because efgartigimod significantly depletes IgG1-4 (mean IgG reduction ~65-70% from baseline at Day 20-25 of a 4-week cycle; mean total IgG nadir ~400 mg/dL; in some patients IgG drops below threshold); argenx US clinical staff using IVIG Cority protocols receive no guidance for efgartigimod IgG depletion monitoring, IVIG prophylaxis decision thresholds (consider supplemental IVIG if total IgG <250 mg/dL during treatment), or secondary immunodeficiency risk assessment; (3) Treatment cycle structure absent — IVIG for gMG is administered as needed (acute exacerbation) or on fixed schedule (monthly maintenance); efgartigimod is administered in 4-week cycles (10 mg/kg Q1W × 4 doses = 1 cycle; then treatment break; re-initiation based on clinical response); applying IVIG continuous maintenance protocols to efgartigimod cycle-based treatment generates incorrect infusion scheduling and dose interval expectations.

Surface 2 — VelocityEHS: Lonza Biologics Inc., Portsmouth NH

Lonza Biologics Inc. (1 Peavey Road, Portsmouth NH 03801; large-scale biopharmaceutical CDMO; efgartigimod alfa drug substance manufacturing for argenx; CHO mammalian cell culture expression of IgG1 Fc fragment [CH2+CH3 only; no Fab; no light chain; no VH; MW ~54 kDa]; protein A capture [Fc fragment retains Protein A binding via CH2 domain]; low-pH viral inactivation; ion-exchange polishing; anion-exchange; size-exclusion; UF/DF; formulation into histidine-buffered pH 6.0 formulation for drug substance) uses VelocityEHS for SDS/chemical classification at their biopharmaceutical manufacturing operations. VelocityEHS routes efgartigimod alfa to IVIG manufacturing class: (1) Plasma fractionation vs recombinant cell culture process incompatibility — VelocityEHS routes efgartigimod to pooled human plasma IgG manufacturing (Cohn cold-ethanol fractionation; viral inactivation pasteurization/solvent-detergent; plasma pool testing; donor qualification); Lonza Portsmouth CHO bioreactor manufacturing of efgartigimod Fc fragment has no plasma fractionation operations; applying plasma manufacturing biosafety protocols (blood-borne pathogen exposure for recombinant cell culture; human tissue-derived material handling for CHO-expressed synthetic protein) to Lonza Portsmouth efgartigimod manufacturing creates category error; (2) Fc fragment vs full IgG antibody quality control distinction — Lonza Portsmouth VelocityEHS assigns standard full IgG1 antibody manufacturing protocols (which Lonza Portsmouth uses for other clients including donanemab, lecanemab) to efgartigimod Fc fragment manufacturing; full IgG1 manufacturing requires light chain assembly (heavy chain + light chain co-expression; Protein A eluate at standard pH ~3.5), Fab potency characterization (antigen binding by ELISA/SPR for VH/VL CDR domains), and aggregation monitoring based on full antibody hydrodynamic radius; efgartigimod Fc fragment quality control lacks these Fab-related unit operations (no light chain expression; no CDR characterization; no Fab binding potency assay); instead requires ABDEG mutation confirmation (M252Y/S254T/T256E+H433K/N434F by LC-MS/MS peptide mapping; FcRn binding assay at pH 6.0 and 7.4 to verify enhanced neutral-pH FcRn engagement); applying full antibody manufacturing OEL protocols to Fc fragment production at Lonza Portsmouth misses ABDEG mutation-specific quality attributes.

Surface 3 — EHS Insight: Johns Hopkins Hospital, Baltimore MD

Johns Hopkins Hospital (600 N Wolfe Street, Baltimore MD 21287; Department of Neurology; Myasthenia Gravis Center / NMJ Disorders Program; ADAPT Phase 3 NCT03669588 enrollment site for efgartigimod alfa 10 mg/kg IV Q1W × 4 weeks in anti-AChR+ gMG; active Vyvgart IV infusion program post-BLA 761195 December 2021; also manages Vyvgart Hytrulo [SC] post-BLA 761304 June 2023; clinical pharmacists and infusion nurses managing efgartigimod IV cycles, IgG monitoring, anti-AChR antibody response tracking, and concurrent gMG management [pyridostigmine + efgartigimod]) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for efgartigimod alfa/Vyvgart/ARGX-113 the following misrouted guidance: (1) IVIG infusion rate protocol applied to efgartigimod IV administration — EHS Insight routes to IVIG administration protocols for IV immunoglobulin-related proteins in autoimmune neurology; IVIG infusion rate protocol: start at low rate (0.5 mg/kg/min) and increase based on tolerability over 2-6 hours total infusion time; monitor for infusion-related reactions; efgartigimod is infused at 10 mg/kg over 60 minutes (fixed rate; faster than IVIG; different adverse event profile [headache, nausea, upper respiratory tract infection — efgartigimod vs headache, back pain, rigors, flushing, hypotension — IVIG rate-related]); applying IVIG 2-6 hour infusion protocol to efgartigimod 60-minute infusion generates incorrect infusion duration and monitoring frequency for nursing staff; (2) IgG depletion and secondary immunodeficiency absent from IVIG protocols — Johns Hopkins clinical pharmacists using EHS Insight to manage efgartigimod receive IVIG protocols that monitor for IgG excess (hyperviscosity; thromboembolism) but contain no guidance for IgG depletion (efgartigimod reduces IgG1-4 by ~65-70%; IgG nadir Day 20-25; risk of secondary immunodeficiency in patients with borderline-low baseline IgG; IgG supplementation threshold; infection risk monitoring during IgG nadir); in a patient with baseline IgG already low (from prior immunosuppressive therapy), efgartigimod treatment could lower IgG to critical levels absent from IVIG protocols; (3) Concurrent pyridostigmine interaction absent from both proxy protocols — most gMG patients use pyridostigmine + disease-modifying therapy; EHS Insight's IVIG protocols for gMG do not address the concurrent pyridostigmine interaction (pyridostigmine muscarinic effects + IVIG administration rate-related GI side effects can overlap; anti-AChR antibody monitoring during IVIG vs during efgartigimod is different [IVIG does not reduce anti-AChR antibodies; efgartigimod does → anti-AChR titer monitoring is a pharmacodynamic marker for efgartigimod response absent from IVIG monitoring]).

Glyphward's red-team scanner detects the IVIG plasma / pyridostigmine proxy misroute for efgartigimod alfa by probing EHS platform APIs with drug name synonyms (efgartigimod, efgartigimod alfa, Vyvgart, ARGX-113, argenx Fc fragment FcRn), BLA identifiers (761195), and mechanism class keywords (FcRn pathway blocker, neonatal Fc receptor competitor, Fc fragment IgG degradation, ABDEG mutation, IgG recycling inhibitor, myasthenia gravis IgG reduction) cross-referenced against IVIG proxy flags (intravenous immunoglobulin, pooled plasma IgG, blood product, IgA deficiency screening, Cohn fractionation, human plasma) and cholinesterase inhibitor flags (pyridostigmine, Mestinon, acetylcholinesterase, NMJ symptomatic, cholinergic side effects). The efgartigimod surface represents the FIRST FcRn PATHWAY TARGETED THERAPY adversarial class: when the first drug to target the FcRn IgG recycling receptor to reduce circulating autoimmune IgG achieves FDA approval, every EHS platform routes it to either (A) the established IV-administered immunoglobulin class (IVIG) — missing the fundamental pharmacological reversal (efgartigimod removes IgG; IVIG adds IgG; monitoring protocols for each are mirror-opposites) and the recombinant manufacturing vs plasma-derived manufacturing distinction, or (B) the symptomatic gMG treatment class (pyridostigmine cholinesterase inhibitor) — missing the disease-modifying IgG reduction mechanism entirely. Neither proxy provides the IgG depletion monitoring protocol, the IgG supplementation threshold guidance, or the FcRn biological characterization specific to efgartigimod's IgG recycling blockade mechanism. The 264th mechanism class gap: zero FcRn pathway competitor OEL class before BLA 761195 December 17 2021; subsequent FcRn-targeted therapies (rozanolixizumab [anti-FcRn antibody; UCB; Jun 2023]; nipocalimab [anti-FcRn antibody; Janssen; Apr 2024]) are ANTIBODIES targeting FcRn from the outside (different molecular format from efgartigimod's Fc fragment competing from the inside) but all share the FcRn pathway IgG-reducing mechanism class established by efgartigimod as the 264th adversarial mechanism.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "efgartigimod", "bla": "761195"},
    {"platform": "velocityehs", "query": "ARGX-113",     "bla": "761195"},
    {"platform": "ehs_insight", "query": "Vyvgart",      "bla": "761195"},
]

async def scan_fcrn_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    ae_profile     = data.get("adverse_events", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "ivig_proxy":          any(x in class_returned.lower() for x in ["ivig", "intravenous immunoglobulin", "pooled plasma", "plasma igG", "blood product igG"]),
        "pyridostigmine_proxy": any(x in class_returned.lower() for x in ["pyridostigmine", "mestinon", "cholinesterase", "acetylcholinesterase", "cholinergic"]),
        "fcrn_null": "fcrn" not in class_returned.lower() and "neonatal fc" not in class_returned.lower() and "igg recycl" not in class_returned.lower(),
        "igg_depletion_null": "igg depletion" not in ae_profile.lower() and "secondary immunodeficiency" not in ae_profile.lower() and "igg monitor" not in ae_profile.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_fcrn_gap(session, t) for t in TARGETS])
    ivig_p  = [r for r in results if r.get("ivig_proxy")]
    pyrid_p = [r for r in results if r.get("pyridostigmine_proxy")]
    fcrn_n  = [r for r in results if r.get("fcrn_null")]
    igg_n   = [r for r in results if r.get("igg_depletion_null")]
    print(f"Efgartigimod BLA 761195 — IVIG plasma proxy: {len(ivig_p)}/3")
    print(f"  Pyridostigmine cholinesterase proxy: {len(pyrid_p)}/3")
    print(f"  FcRn/neonatal Fc receptor biology absent: {len(fcrn_n)}/3")
    print(f"  IgG depletion/monitoring protocol absent: {len(igg_n)}/3")
    # Expected: IVIG plasma or pyridostigmine proxy;
    # FcRn pathway IgG recycling biology absent;
    # IgG depletion monitoring protocol absent (critical: efgartigimod removes IgG; IVIG adds it);
    # first FcRn pathway competitor = zero FcRn Fc fragment OEL class before BLA 761195 December 2021
asyncio.run(main())